Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.86 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.73 |
| ▸ | HTR2B | P41595 | 3/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.61 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318012 | 0.93 | P2RY1 (0.98) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19503293 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19464926 | 0.91 | P2RY1 (0.72) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19459519 | 0.90 | P2RY1 (0.71) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL19807532 | 0.88 | P2RY1 (0.78) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL29318115 | 0.88 | P2RY1 (0.78) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL25613499 | 0.87 | P2RY1 (0.67) | P2RY1P2RY2ADORA3HTR2BHTR2C | |
| SCHEMBL10120961 | 0.86 | P2RY1 (1.00) | P2RY1P2RY2ADORA3ADORA1ADORA2A | |
| SCHEMBL19464862 | 0.86 | P2RY1 (1.00) | P2RY1P2RY2ADORA3ADORA1ADORA2A | |
| SCHEMBL12269663 | 0.86 | P2RY1 (1.00) | P2RY1P2RY2ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |